Pfizer Inc. said its Lipitor drug reduces the risk of stroke, coronary heart disease events and major coronary events in type-2 diabetes patients.
The trial indicated that Lipitor reduced the risk of stroke by 30%, and coronary heart disease events and major coronary events, including cardiac death and heart attack, by 51%, compared with a placebo. An additional analysis of 781 patients showed that Lipitor reduced the risk of coronary heart disease events by 43%. The risk of stroke and major coronary events was lowered by 12% and 26%, respectively.